Focus Partners Advisor Solutions’s AstraZeneca AZN Stock Holding History

Focus Partners Advisor Solutions’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$990K	Buy	5,223 +114	+2%	+$21.4K	0.01%	578
2026 Q1	$970K	Buy	5,109 +702	+16%	+$135K	0.01%	568
2025 Q4	$810K	Sell	4,407 -747	-14%	-$131K	0.01%	562
2025 Q3	$875K	Buy	5,154 +1,802	+54%	+$273K	0.01%	576
2025 Q2	$469K	Buy	3,352 +12	+0.4%	+$1.68K	0.01%	698
2025 Q1	$491K	Buy	3,340 +821	+33%	+$119K	0.01%	591
2024 Q4	$330K	Sell	2,519 -528	-17%	-$73.9K	0.01%	579
2024 Q3	$475K	Buy	3,047 +969	+47%	+$156K	0.01%	464
2024 Q2	$324K	Sell	2,078 -1,316	-39%	-$198K	0.01%	472
2024 Q1	$460K	Buy	3,394 +1,290	+61%	+$171K	0.01%	377
2023 Q4	$283K	Buy	2,104 +501	+31%	+$65.1K	0.01%	337
2023 Q3	$217K	Buy	+1,603	New	+$219K	0.01%	410

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Focus Partners Advisor Solutions's AZN Position: Q2 2026 in Review

Focus Partners Advisor Solutions increased its AstraZeneca (AZN) stake by 2.2% in Q2 2026, buying an estimated $21.4K and bringing the position to 5,223 shares worth $990K. The position accounts for 0.01% of the portfolio, ranked #578.

Focus Partners Advisor Solutions first reported a position in AZN in Q3 2023 and has held it in 12 quarters since. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Focus Partners Advisor Solutions held 5,223 shares of AstraZeneca worth $990K as of Q2 2026.
Focus Partners Advisor Solutions bought 114 AstraZeneca shares in Q2 2026, an estimated $21.4K.
AstraZeneca made up 0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #578 holding.
Focus Partners Advisor Solutions first reported a position in AstraZeneca in Q3 2023 and has held it in 12 quarters since.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.